cabozantinib

Org: Sidney Kimmel Cancer Center at Thomas Jefferson University, Thomas Jefferson University Hospital, Center for Head and Neck Cancers, Massachusetts General Hospital, Medical Oncology Department. Vall Hebron University Hospital,

Abstract

Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC).

Org: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Georgetown-Lombardi Comprehensive Cancer Center, Bristol Myers Squibb, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center,

Abstract

Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals.

Org: Lifespan Cancer Institute, Brown University School of Medicine-Rhode Island Hospital, Rhode Island Hospital, Stanford University School of Medicine, The University of Texas MD Anderson Cancer Center,

Abstract

Cabozantinib plus atezolizumab in patients with advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II trial (CABATEN / GETNE-T1914).

Org: University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario 12 de Octubre, Imas12, UCM, Hospital Universitario La Paz, IdiPAZ, Hospital Universitario Central de Asturias, ISPA, Catalan Institute of Oncology (ICO-Badalona) Germans Trias i Pujol University Hospital,

Abstract

STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.

Org: Winship Cancer Institute, Emory University, Atlanta, GA, USA, The Institute of Cancer Research/The Royal Marsden Hospital, Fondazione IRCCS Istituto Nazionale Tumori and University of Milan, Cliniques Universitaires Saint-Luc,

Abstract

Lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial.

Org: University Hospital Essen, Memorial Sloan Kettering Cancer Center, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Department of Urology and Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany, Medical University of Vienna,

Abstract

FDA analysis of immune checkpoint inhibitors in combination with vascular endothelial growth factor tyrosine kinase inhibitors in the second-line treatment of patients with advanced non-small cell lung cancer.

Org: U.S. Food and Drug Administration, Silver Spring, MD, Office of Oncologic Diseases, Center for Drug Evaluation and Research, Oncology Center of Excellence,

Abstract

Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma.

Org: Winship Cancer Institute of Emory University, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA,

Abstract

Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial.

Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, DFCI/PCC Fellowship Program - Attendings, Yale Cancer Center,

Abstract

Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,

Abstract

FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors.

Org: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Carbone Cancer Center, University of Wisconsin, Madison, WI, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL,

Abstract

Phase 2 trial for sequential treatment of high dose cabozantinib (CABO) or CABO plus nivolumab (NIVO) on/after progression on CABO monotherapy in advanced renal cell carcinoma (RCC): Seq-Cabo.

Org: Peter O’Donnell Jr. School of Public Health,

Abstract

Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study.

Org: University of Miami Hospital and Clinics, Cancer Research Services, New York Oncology Hematology, Moscow City Clinical Oncology Hospital No. 1, Alexandra General Hospital,

Abstract

A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC).

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Indiana University Simon Comprehensive Cancer Center, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, University of Chicago, Chicago, IL, Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Milwaukee, WI, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Mary Crowley Cancer Research, Dallas, TX, AdventHealth Cancer Institute, Orlando, FL, Sarah Cannon Research Institute, Nashville, TN, St. Jude Crosson Cancer Institute/Providence Medical Foundation, Fullerton, CA, Fort Wayne Medical Oncology - West Jefferson Office, Fort Wayne, IN, Scholar Rock Inc., Cambridge, MA, Scholar Rock, Cambridge, MA, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,

Abstract

Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC).

Org: Miyarisan Pharmaceutical Co., Ltd., Saitama, Japan,

Abstract

Anti-angiogenic TKIs in patients with advanced Ewing sarcoma: A systematic review and single-arm meta-analysis.

Org: Universidade Estadual do Centro Oeste (UNICENTRO), Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Emily Couric Clinical Cancer Center, University of Virginia,

Abstract

Enhancing the efficacy of anti-PD-L1 therapy by cabozantinib in the treatment of advanced esophageal squamous cell carcinoma (ESCC): Rationales from a preclinical study.

Org: National Taiwan University Cancer Center/Hospital, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, National Taiwan University Hospital Yunlin Branch,

Abstract

Cabozantinib outcomes for metastatic renal cell carcinoma at a tertiary NHS hospital in the United Kingdom (UK).

Org: Norfolk and Norwich University Hospitals NHS Trust, Norwich, United Kingdom, Norfolk and Norwich University Hospitals NHS Foundation Trust,

Abstract

Cabozantinib (CABO) after prior immune checkpoint inhibitor (ICI) and tyrosine-kinase inhibitors (TKI) therapy in metastatic renal cell carcinoma (mRCC): Real-world evidence (RWE) from a Moscow observational program.

Org: SBIH Moscow Clinical Scientific and Practical Center Named After A.S. Loginov, Moscow, Russian Federation,

Abstract

Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).

Org: Alberta, Canada, Sunnybrook Odette Cancer Centre,

Clinical trial

A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)

Status: Active (not recruiting), Estimated PCD: 2024-08-01

Abstract

Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial.

Org: City of Hope Comprehensive Cancer Center, CanSino Biologics, Flagstaff, Yale University School of Medicine, CTI BioPharma,

Abstract

A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).

Org: Duke University Medical Center, Mayo Clinic, Vanderbilt University Medical Center, Virginia Commonwealth University Health System, Duke Cancer Institute,

Abstract

A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas.

Org: Mayo Clinic, Northwestern University, UCSF Helen Diller Family Comprehensive Cancer Center, University of Iowa, City of Hope National Medical Center,

Abstract

Randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma.

Org: Washington University Siteman Cancer Center, St. Louis, MO, Washington University School of Medicine, Washington University in Saint Louis, University of Colorado Cancer Center, University of Pennsylvania-Abramson Cancer Center,

Abstract

Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.

Org: Dana-Farber Cancer Institute, Gustave Roussy Cancer Center, Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 de Octubre,

Abstract

Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial.

Org: IRCCS Foundation National Cancer Institute, Milan, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, IRCCS Ospedale San Raffaele, Milan, Italy, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy,

Abstract

Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma.

Org: Novartis Pharma AG, F. Hoffmann-La Roche Ltd, Exelixis, Inc., VBL Therapeutics, Dana-Farber Cancer Institute,

Abstract

Org: Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, Bristol Myers Squibb, Princeton, NJ, Exelixis, Inc., Alameda, CA, IQVIA, Amsterdam, Netherlands,

Abstract

CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC).

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, Mayo Clinic, Winship Cancer Institute of Emory University,

Abstract

LUNG-IST-127: A pilot phase II study of maintenance cabozantinib plus pembrolizumab for patients with metastatic squamous non-small cell lung cancer (sqNSCLC) with disease control following induction therapy.

Org: Department of Hematology Oncology University of Illinois of Chicago College of Medicine, University of Ilinois Chicago, Department of Surgery University of Illinois of Chicago College of Medicine, University of Illinois Chicago, Jesse Brown VAMC,

Abstract

Pathologic concordance rate and outcomes by histologic subtype in advanced papillary renal cell (pRCC) carcinoma: An analysis from the SWOG S1500 (PAPMET) trial.

Org: City of Hope Comprehensive Cancer Center, SWOG Statistics and Data Management Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Yale School of Medicine, Yale University,

Abstract

STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer.

Org: David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Exelixis, Inc.,

Abstract

CASSIOPE: A prospective noninterventional study of cabozantinib treatment following prior vascular endothelial growth factor (VEGF) -targeted therapy in patients with advanced renal cell carcinoma (aRCC).

Org: University of Munich, Muenchen, Germany, Centre Hospitalier Universitaire d'Angers, Angers, France, Institut de Cancérologie Strasbourg Europe, Strasbourg, France, Department of Medical Oncology, Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain,

Abstract

Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).

Org: Vanderbilt-Ingram Cancer Center, University of Texas MD Anderson Cancer Center, University of Pennsylvania-Abramson Cancer Center, Cleveland Clinic Taussig Cancer Instititute, Massachusetts General Hospital Cancer Center and Harvard Medical School,

Abstract

Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.

Org: University of Calgary, Texas Oncology PA, Ipsen, Ontada, McMaster University and Juravinski Cancer Centre,

Abstract

CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).

Org: Washington University School of Medicine in St Louis, Saint Lukes Hospital,

Abstract

Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).

Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, Department of Data Sciences, Winship Cancer Institute of Emory University,

Abstract

A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.

Org: Memorial Sloan Kettering Cancer Center,

Abstract

Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma.

Org: Rush University Medical School, FibroFighters Foundation, Nagourney Cancer Institute, FibroFighters.org, Rush University Medical Center,

Abstract

Association of 18F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies.

Org: National Cancer Institute, Vilnius, Lithuania, National Institutes of Health Division of Occupational Health and Safety, Genitourinary Malignancies Branch, CCRT/The Caroline Foundation, NCI,

Abstract

Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial.

Org: Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, Memorial Sloan Kettering Cancer Center and Weill Cornell College of Medicine,

Abstract

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).

Org: Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York-Presbyterian Hospital, The Tisch Cancer Institute,

Abstract

Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naïve patients with advanced clear cell RCC.

Org: University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, MD Anderson Cancer Center,

Abstract

CD8 cell PET imaging with 89-Zr-crefmirlimab berdoxam (crefmirlimab) in patients with metastatic renal cell carcinoma (mRCC) receiving checkpoint inhibitors (CPIs): Association with response and tissue CD8 expression.

Org: City of Hope National Medical Center, John Wayne Cancer Institute, University of Washington and Fred Hutchinson Cancer Research Centre, CARTI Cancer Center, ImaginAb,

Abstract

Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.

Org: FDA/CDER, U.S. Food and Drug Administration, US Food and Drug Administration, Oncology Center of Excellence, Office of New Drugs,

Abstract

PEMBROCABOSARC: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas.

Org: Institut Bergonie, Institut Bergonié, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Institut Paoli Calmettes, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,

Abstract

Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma.

Org: Georgetown - Lombardi Comprehensive Cancer Center, John Theurer Cancer Center at Hackensack Meridian Health, HMH School of Medicine, Hackensack, NJ, Washington Cancer Institute/Georgetown-Lombardi Comprehensive Cancer Center, Medstar Franklin Square Medical Center, Georgetown Lombardi Comprehensive Cancer Center,

Abstract

Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib + nivolumab +/- ipilimumab.

Org: Genitourinary Malignancies Branch, CCRT/The Caroline Foundation, NCI, Nihon Medi-Physics, Hospital Sírio-Libanês,

Abstract

The emerging use of immunotherapy as a treatment option in metastatic renal cell carcinoma: Real-world evidence from a single UK tertiary cancer centre.

Org: Hull University Teaching Hospitals NHS Trust, University of Leeds, Royal Cornwall Hospital NHS Trust,

Abstract

Real-world treatment sequencing and outcomes for patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy: Results from the CARINA study.

Org: Mount Vernon Cancer Center, Northwood, United Kingdom, Christie NHS Foundation Trust, Manchester, United Kingdom, Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom, Royal Preston Hospital,

Abstract

Nivolumab usage patterns combined with TKI for mRCC: Financial toxicity and clinical outcomes from self-paying patients in India—Is low dose an option when access is limited?

Org: Christian Medical College & Hospital Vellore, Christian Medical College Vellore, Department of Uro-Oncology, Chongqing University Cancer Hospital, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,

Abstract

FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes.

Org: National Cancer Institute, Vilnius, Lithuania, Nihon Medi-Physics, Cleveland Clinic Taussig Cancer Instititute, Medical College of Wisconsin, NYU Langone Laura and Isaac Perlmutter Cancer Center,

Abstract

Retrospective analysis of the multikinase inhibitor (MKI) pazopanib in differentiated thyroid carcinoma (DTC) in the beyond-first-line setting.

Org: Mayo Clinic, University of Missouri–Kansas City, Mayo Clinic Florida,

Abstract

Treatment patterns post atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: Real-world analysis at Veterans Health Administration comparing lenvatinib vs. sorafenib.

Org: Univeristy of Texas Health Science Center San Antonio, San Antonio, TX, University of Texas Health Science Center at San Antonio, San Anonio, TX, The University of Texas Health Science Center-San Antonio,

Abstract

Genomic mechanisms of RET inhibitor sensitivity and resistance in RET-fusion positive cancer cells.

Org: Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, MD Anderson Cancer Center, UT Southwestern Medical Center,

Abstract

Antitumor activity of AX-0085, a novel AXL kinase inhibitor: Analysis of apoptotic cell death in triple-negative breast cancer cells.

Org: Axceso Biopharma Co., Ltd., College of Medicine, Hanyang University, Department of Life Science, Ewha Womans University, Ewha Research Center for Systems Biology, Ewha Womans University, College of Pharmacy, Seoul National University,

Abstract

Development of a kidney cancer ex vivo tumor model and image-based artificial intelligence tool for precision immunotherapy and combination therapy testing.

Org: Ourotech Ltd t/a Pear Bio, Royal Free London NHS Foundation Trust,

Abstract

Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).

Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,

Abstract

Correlations between overall response rate, progression-free survival and overall survival with kinase inhibitors in radioiodine-refractory differentiated thyroid cancers: A systematic review and meta-analysis.

Org: One Brooklyn Health/Brookdale University Hospital and Medical Center, Brooklyn ImmunoTherapeutics, Nykode Therapeutics,

Abstract

Outcomes and safety of subsequent treatments after immune- and anti-VEGF therapy in patients with metastatic clear-cell renal cell carcinoma: Outcomes from a tertiary referral hospital.

Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barts Cancer Institute, Barts Health NHS Trust and the Royal Free NHS Foundation Trust,

Product

cabozantinib plus durvalumab

Product

pamiparib and cabozantinib

Product

Cabozantinib + Nivolumab + Ipilimumab

Product

cabozantinib + durvalumab

Product

CAB-ROR2-ADC

Abstract

Real-life use of cabozantinib as front-line therapy in metastatic renal cell carcinoma: The CabFRONT (Meet-URO 24) study.

Org: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Health Sciences, University of Florence, Florence, Italy, Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy, Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy,

Product

Cabozantinib + Atezolizumab

Product

Immune checkpoint inhibitors plus angiogenesis inhibitors

Product

cabozantinib + nivolumab + abiraterone/prednisone

Product

targeted therapies